Source:http://linkedlifedata.com/resource/pubmed/id/17874423
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2007-10-30
|
| pubmed:abstractText |
Epstein-Barr virus-induced gene 3 (EBI3) and the p35 subunit of IL-12 have been reported to form a heterodimeric hematopoietin in human and mouse. We have constructed a heterodimeric protein covalently linking EBI3 and p35, to form a novel cytokine which we now call IL-35. The Fc fusion protein of IL-35 induced proliferation of murine CD4(+)CD25(+) and CD4(+)CD25(-) T cells when stimulated with immobilized anti-CD3 and anti-CD28 antibodies in vitro. The IL-35-expanded CD4(+)CD25(+) T cell population expressed Foxp3 and produced elevated levels of IL-10, whereas the IL-35-induced CD4(+)CD25(-) T cells produced IFN-gamma but not IL-4. The in vitro expanded CD4(+)CD25(+) T cells retained their suppressive functions against CD4(+)CD25(-) effector cells. Furthermore, when cultured with soluble anti-CD3 antibody and antigen-presenting cells, IL-35 suppressed the proliferation of CD4(+)CD25(-) effector cells. Moreover, IL-35 inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0014-2980
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3021-9
|
| pubmed:meshHeading |
pubmed-meshheading:17874423-Animals,
pubmed-meshheading:17874423-Arthritis, Experimental,
pubmed-meshheading:17874423-Blotting, Western,
pubmed-meshheading:17874423-Cell Differentiation,
pubmed-meshheading:17874423-Cell Proliferation,
pubmed-meshheading:17874423-Humans,
pubmed-meshheading:17874423-Interleukin-12 Subunit p35,
pubmed-meshheading:17874423-Interleukins,
pubmed-meshheading:17874423-Lymphocyte Activation,
pubmed-meshheading:17874423-Male,
pubmed-meshheading:17874423-Mice,
pubmed-meshheading:17874423-Mice, Inbred BALB C,
pubmed-meshheading:17874423-Mice, Inbred DBA,
pubmed-meshheading:17874423-Recombinant Proteins,
pubmed-meshheading:17874423-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17874423-T-Lymphocyte Subsets,
pubmed-meshheading:17874423-T-Lymphocytes, Regulatory
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells.
|
| pubmed:affiliation |
Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|